Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  ofatumumab
Find trials that include:  Any drugs shown
Results 1-18 of 18 for your search:
Start Over
Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 113676, NCI-2012-01195, NCT01200589
A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: IPI-145-12, NCI-2014-02041, NCT02049515
Bendamustine Hydrochloride, Ofatumumab, Carboplatin, and Etoposide in Treating Patients with Relapsed or Refractory Aggressive B-cell Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 11D.404, NCI-2011-03434, 152, 2011-61, NCT01458366
Ofatumumab and Prednisone in Treating Patients with Chronic Graft-Versus-Host Disease
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MCC-17071, NCI-2012-02451, 00008286, COMB157EUS03T, NCT01680965
Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 114612, NCI-2011-01815, OFB114612, NCT01294579
Alemtuzumab and Ofatumumab in Treating Patients with Previously Untreated Chronic Lymphocytic Leukemia
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: NU 10H06, NCI-2011-00514, 114699, 114813, 2010-024389-23, STU00044115, NCT01361711
Combination Chemotherapy and Ofatumumab in Treating Patients with Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: Not specified
Trial IDs: 2010-0708, NCI-2011-01061, NCT01363128
Ofatumumab, Etoposide, and Cytarabine Followed By Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 112525, NCI-2012-00863, NCT01555541
Ofatumumab and Fresh Frozen Plasma in Treating Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UCDCC#232, NCI-2013-00118, 333961, OFT116066, NCT01716208
Idelalisib and Ofatumumab in Treating Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-309, NCI-2014-01554, IN-US-312-1237, NCT02135133
Augmented Berlin-Frankfurt-Munster Therapy and Ofatumumab in Treating Patients with B-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 12 to 30
Trial IDs: 2014-0396, NCI-2015-00967, NCI-2010-01164, NCI-2012-01650, NCT02419469
Bendamustine Hydrochloride, Pentostatin, and Ofatumumab in Treating Patients with Previously Treated Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 11P.166, NCI-2011-02341, 2011-23, NCT01352312
Recombinant Human IL-18 and Ofatumumab after PBSCT for Lymphoma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IUCRO-0397, NCI-2013-00003, NCT01768338
Buparlisib and Ofatumumab or Ibrutinib in Treating Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: Winship2494-13, NCI-2015-00652, CBKM120ZUS36T, OSUCC-OFA-BKM120-CLL, NCT02614508
Ofatumumab with or without Bendamustine Hydrochloride in Treating Patients with Mantel Cell Lymphoma That Are Ineligible for Stem Cell Transplant
Status: Active
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: 11-050, NCI-2011-03128, NCT01437709
Start Over